Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextrorphan (DXO) is a psychoactive drug of the morphinan class. It acts as an antitussive or cough suppressant and, at high doses, as a dissociative hallucinogen. Dextrorphan is the major active metabolite of dextromethorphan, produced by O-demethylation via CYP2D6. It is more potent than its parent compound as an NMDA receptor antagonist and has less activity as a serotonin reuptake inhibitor but retains norepinephrine reuptake inhibition. Dextrorphan also has higher affinity for opioid receptors than dextromethorphan at high doses[5]. The pharmacology of dextrorphan contributes to the psychoactive effects observed with excessive use of dextromethorphan-containing products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrorphan.